Sage Healthcare adds directors in the US and Europe

Sage Healthcare has appointed Joe Smith in the United States and Dr Rino Coladangelo in the United Kingdom as directors, expanding its transatlantic dealmaking bench. The hires are aimed at strengthening the firm’s licensing, M&A, financing and transaction execution work for biotechnology, pharmaceutical and healthcare clients.

Why it matters: - Sage Healthcare is adding senior dealmakers as biotechnology, pharmaceutical and health-technology companies face tougher licensing, regulatory and financing conditions. - The two appointments expand the firm’s ability to support cross-border transactions in the US and Europe. - The hires also deepen Sage Healthcare’s bench for partnerships, acquisitions and capital raising.

What happened: - Sage Healthcare Ltd announced two senior appointments to its international team on November 4, 2026. - Joe Smith joined as Director, based in the United States. - Dr Rino Coladangelo joined as Director, based in the United Kingdom. - Both executives will work with Sage Healthcare’s global team on strategic partnerships and transactions.

The details: - Joe Smith brings more than 20 years of experience in M&A, partnerships, capital markets and strategy development. - Joe Smith has led or helped execute more than 40 healthcare corporate transactions totaling more than $32 billion. - Joe Smith has supported more than $200 million in equity financings. - Joe Smith previously held senior corporate and business development roles at Impel, OncoSec, EyePoint, Valeant, Adare and Aton. - Joe Smith founded BioVerity Partners in 2023 to provide fractional leadership to development-stage biopharma companies. - Joe Smith also has management consulting experience at Navigant and Easton Associates, plus capital markets experience at Lazard and Bear Stearns. - Joe Smith earned an M.S. and B.S. in Biomedical Engineering from the University of Pennsylvania and a Certification in Corporate Finance and Accounting from the Wharton School. - Dr Rino Coladangelo has experience in clinical medicine, NHS management, pharmaceutical services, manufacturing compliance and corporate finance. - Dr Rino Coladangelo was Managing Director of Clinical Services at North Hertfordshire NHS Trust. - Dr Rino Coladangelo co-founded the healthcare market-research business Medix UK. - Dr Rino Coladangelo later served as CEO of Rephine, the global pharmaceutical quality and regulatory consultancy. - Rephine was sold to private equity in 2021. - Dr Rino Coladangelo is currently Managing Director of Toro Corporate Finance, which advises on funding for pharmaceutical and life-sciences projects. - Dr Rino Coladangelo’s expertise includes GMP and GCP compliance, regulatory affairs, quality systems and pharmaceutical operations in major international markets. - Dr Rino Coladangelo trained in medicine at the University of London and holds MB BS and MRCP qualifications. - Sage Healthcare said the hires add complementary expertise in global licensing, M&A, pharma transactions and financing. - Dr William Mason said the appointments strengthen Sage Healthcare’s senior team in the US and Europe and improve advice and execution capabilities for clients worldwide. - Joe Smith said Sage Healthcare’s global presence and SAGEIQ intelligence platform will help support clients through partnerships, acquisitions and financing opportunities. - Dr Rino Coladangelo said the role comes as life-sciences companies navigate more demanding development, regulatory and funding environments.

Between the lines: - Sage Healthcare is signaling a push to compete on execution, not just advisory coverage, by pairing transaction experience with regulatory and clinical expertise. - The combination of a US-based dealmaker and a UK-based physician-executive suggests the firm is building for more transatlantic mandates. - The reference to SAGEIQ shows Sage Healthcare positioning AI-enabled intelligence as part of its client offering.

What's next: - Sage Healthcare will use the expanded team to pursue licensing, partnership, acquisition and financing mandates globally. - The firm is likely to lean on the new directors to support clients across diligence, valuation and transaction execution. - Sage Healthcare will continue working through its offices and affiliated teams across North America, Europe, China, Israel and Asia-Pacific.

The bottom line: - Sage Healthcare is betting that deeper senior expertise in the US and Europe will help it win more complex life-sciences transactions worldwide. - More information is available on Sage Healthcare and Partner BioKinect.